Sandra Blasco-Benito

Sandra Blasco-Benito

Auto-generated profile, based on publicly available information

Sandra Blasco-Benito

Cancer Research Program Hospital del Mar Research Institute (HMRI) Barcelona Spain

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Biochemical Pharmacology
Verified
Journal Article
Closed access
SBSandra Blasco-Benito
Sandra Blasco-Benito
MSMarta Seijo-Vila
Marta Seijo-Vila
MCMiriam Caro-Villalobos
Miriam Caro-Villalobos
ITIsabel Tundidor
Isabel Tundidor
CAClara Andradas
Clara Andradas
CSCristina Sánchez
Cristina Sánchez

8 April 2015 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
EPEduardo Pérez-Gómez
Eduardo Pérez-Gómez
CAClara Andradas
Clara Andradas
SBSandra Blasco-Benito
Sandra Blasco-Benito
MCMaria Caffarel
Maria Caffarel
EGElena García-Taboada
Elena García-Taboada
CSCristina Sánchez
Cristina Sánchez
Pharmacological activation of cannabinoid receptors elicits antitumoral responses in different cancer models. However, the biological role of these receptors in tumor physio-pathology is still unknown. We analyzed CB2 cannabinoid receptor protein expression in two series of 166 and 483 breast tumor samples operated in the University Hospitals of Kiel, Tübingen, and Freiburg between 1997 and 2010 and CB2 mRNA expression in previously published DNA microarray datasets. The role of CB2 in oncogenesis was studied by generating a mouse line that expresses the human V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) rat ortholog (neu) and lacks CB2 and by a variety of biochemical and cell biology approaches in human breast cancer cells in culture and in vivo, upon modulation of CB2 expression by si/shRNAs and overexpression plasmids. CB2-HER2 molecular interaction was studied by colocalization, coimmunoprecipitation, and proximity ligation assays. Statistical tests were two-sided. We show an association between elevated CB2 expression in HER2+ breast tumors and poor patient prognosis (decreased overall survival, hazard ratio [HR] = 0.29, 95% confidence interval [CI] = 0.09 to 0.71, P = .009) and higher probability to suffer local recurrence (HR = 0.09, 95% CI = 0.049 to 0.54, P = .003) and to develop distant metastases (HR = 0.33, 95% CI = 0.13 to 0.75, P = .009). We also demonstrate that genetic inactivation of CB2 impairs tumor generation and progression in MMTV-neu mice. Moreover, we show that HER2 upregulates CB2 expression by activating the transcription factor ELK1 via the ERK cascade and that an increased CB2 expression activates the HER2 pro-oncogenic signaling at the level of the tyrosine kinase c-SRC. Finally, we show HER2 and CB2 form heteromers in cancer cells. Our findings reveal an unprecedented role of CB2 as a pivotal regulator of HER2 pro-oncogenic signaling in breast cancer, and they suggest that CB2 may be a biomarker with prognostic value in these tumors.

1 August 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
EMEstefanía Moreno
Estefanía Moreno
CAClara Andradas
Clara Andradas
MMMireia Medrano
Mireia Medrano
MCMaria Caffarel
Maria Caffarel
EPEduardo Pérez-Gómez
Eduardo Pérez-Gómez
CSCristina Sánchez
Cristina Sánchez
The G protein-coupled receptors CB2 (CB2R) and GPR55 are overexpressed in cancer cells and human tumors. Because a modulation of GPR55 activity by cannabinoids has been suggested, we analyzed whether this receptor participates in cannabinoid effects on cancer cells. Here we show that CB2R and GPR55 form heteromers in cancer cells, that these structures possess unique signaling properties, and that modulation of these heteromers can modify the antitumoral activity of cannabinoids in vivo. These findings unveil the existence of previously unknown signaling platforms that help explain the complex behavior of cannabinoids and may constitute new targets for therapeutic intervention in oncology.

7 February 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SBSandra Blasco-Benito
Sandra Blasco-Benito
EMEstefanía Moreno
Estefanía Moreno
MSMarta Seijo-Vila
Marta Seijo-Vila
ITIsabel Tundidor
Isabel Tundidor
CAClara Andradas
Clara Andradas
CSCristina Sánchez
Cristina Sánchez
Significance: There is a subtype of breast cancer characterized by the overexpression of the oncogene HER2. Although most patients with this diagnosis benefit from HER2-targeted treatments, some do not respond to these therapies and others develop resistance with time. New tools are therefore warranted for the treatment of this patient population, and for early identification of those individuals at a higher risk of developing innate or acquired resistance to current treatments. Here, we show that HER2 forms heteromer complexes with the cannabinoid receptor CB 2 R, the expression of these structures correlates with poor patient prognosis, and their disruption promotes antitumor responses. Collectively, our results support HER2–CB 2 R heteromers as new therapeutic targets and prognostic tools in HER2+ breast cancer.

21 June 2016 in Oncotarget
Verified
Journal Article
Open access
CAClara Andradas
Clara Andradas
SBSandra Blasco-Benito
Sandra Blasco-Benito
SCSONIA CASTILLO-LLUVA
SONIA CASTILLO-LLUVA
PDPatricia Dillenburg-Pilla
Patricia Dillenburg-Pilla
RAREBECA DIEZ ALARCIA
REBECA DIEZ ALARCIA
CSCristina Sánchez
Cristina Sánchez
Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer

20 February 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PMPaula Morales
Paula Morales
SBSandra Blasco-Benito
Sandra Blasco-Benito
CAClara Andradas
Clara Andradas
MGMaría Gómez-Cañas
María Gómez-Cañas
JFJuana María Flores
Juana María Flores
NJNadine Jagerovic
Nadine Jagerovic